The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
(10 - 33) Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
200 jobs Number of planned job creations
Announcement Date
4 December 2006
Employment effect (start)
Foreseen end date
31 December 2011
Description
American multinational pharmaceutical company Eli Lilly has unveiled details of a 400 million euro investment, which will create 200 jobs in a new biopharmaceutical facility at its plant near Kinsale, Co Cork. The jobs, which will come on stream over the next five years, will involve recruitment of third-level graduates, many with PhD qualifications, and will bring staff numbers at the plant at Kinsale to 600 in total.
Minister for Enterprise, Trade and Employment, Micheál Martin, welcomed the announcement and said the investment, supported by IDA Ireland, confirmed Ireland's growing importance as an international centre for biopharmaceutical development. "This announcement further strengthens Ireland's, and in particular Cork's, position as the number one location of choice for major biopharmaceutical activity outside the US. It is a major achievement for IDA Ireland to have won this investment against intense global competition," said Mr Martin.
Eli Lilly has been established in Kinsale since 1981 and employs some 400 people in manufacturing the active ingredients for a number of the company's best known products, schizophrenia treatment, Zyprex, and osteoporosis treatment, Evista. The new biopharmaceuticals facility in Dunderrow will use the latest technology to develop medical proteins to create medicines to treat illnesses including cancer, diabetes and Alzheimer's disease.
Sources
4 December 2006: The Irish Times
Citation
Eurofound (2006), Eli Lilly, Business expansion in Ireland, factsheet number 64583, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/64583.
This working paper offers a comprehensive methodological overview of the European Restructuring Monitor (ERM) databases. Even though the methodology has not changed over time, new categories have been added, and the way it has been used by researchers and policymakers...
This Eurofound research paper explores key trends in restructuring in recent years, highlighting the companies that announced the largest job losses and job gains in the EU. It builds on an analysis of company announcements recorded in Eurofound’s European Restructuring...
In 2023, thousands of workers in big tech lost their jobs. Meta, Amazon, Google, Apple, Microsoft and Salesforce had been considered to offer good and secure jobs up to this point. Giants of the information and communication technology (ICT) sector,...
In 2024, the automotive sector in the EU came to the fore in public and policy discussions. The focus was on the slowdown in electric vehicle (EV) sales, rising global competition, belated investments in new technologies, and the potential closure...
The more employee monitoring resembles surveillance – with its systematic, continuous and detailed tracking of employees' activities, behaviours or communications – the greater the potential for infringement of both privacy and data protection rights. Although the EU General Data Protection...
Since 2013, Eurofound's ERM database on restructuring-related legislation has been documenting regulatory developments in the Member States of the European Union and Norway which are explicitly or implicitly linked to anticipating and managing change. The most recent update to the...